| KEYWORD |
Antimicrobial (drug) resistance and drug discovery
Tesi esterna in azienda
Parole chiave ANTIBIOTICS, DRUG RESISTANCE, BACTERIA, DRUG DESIG
Riferimenti MARCO AGOSTINO DERIU, JACEK ADAM TUSZYNSKI
Riferimenti esterni Prof. Daniel Charlebois, University of Alberta
Gruppi di ricerca 28- biomedica
Descrizione Drug resistance is a health crisis that is undermining advances in modern medicine and is predicted to kill 10 million people per year globally by 2050. The proposed research will involve testing predictions from molecular dynamics simulations (in collaboration with Dr. Jack Tuszynski’s group) and computational modeling via laboratory experiments. These experiments will involve testing novel compounds, as well as common antibiotics and antifungal drugs, on bacteria (E. coli), budding yeast (S. cerevisiae) strains genetically engineered to carry synthetic drug resistance gene networks, and pathogenic yeasts (C. albicans, C. glabrata, and C. auris). The overall aim of this research program is to develop effective, “evolution proof” drug treatment strategies for patients with drug resistant infections. The Charlebois Lab at the University of Alberta, Edmonton, Canada will host the internship student for a period of 4-6 months as part of this project.
Conoscenze richieste basic bioengineering techniques; cell culture
Scadenza validita proposta 21/12/2020
PROPONI LA TUA CANDIDATURA